| Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease A Waxman, R Restrepo-Jaramillo, T Thenappan, A Ravichandran, ... New England Journal of Medicine 384 (4), 325-334, 2021 | 401 | 2021 |
| What factors determine the severity of hepatitis A‐related acute liver failure? V Ajmera, G Xia, G Vaughan, JC Forbi, LM Ganova‐Raeva, Y Khudyakov, ... Journal of viral hepatitis 18 (7), e167-e174, 2011 | 90 | 2011 |
| The neutrophil chemoattractant peptide proline-glycine-proline is associated with acute respiratory distress syndrome NS Sharma, CV Lal, J Li, X Lou, L Viera, T Abdallah, RW King, J Sethi, ... American Journal of Physiology-Lung Cellular and Molecular Physiology 315 (5 …, 2018 | 26 | 2018 |
| Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study A Waxman, R Restrepo-Jaramillo, T Thenappan, P Engel, A Bajwa, ... European Respiratory Journal 61 (6), 2023 | 22 | 2023 |
| Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the … K Zeitler, R Jariwala, R Restrepo-Jaramillo, S Kapadia, B Casanas, ... Case Reports 2018, bcr-2017-223138, 2018 | 20 | 2018 |
| BREEZE: open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension LA Spikes, AA Bajwa, CD Burger, SV Desai, MS Eggert, KA El‐Kersh, ... Pulmonary Circulation 12 (2), e12063, 2022 | 14 | 2022 |
| Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery D Bandyopadhyay, C Lai, JN Pulido, R Restrepo-Jaramillo, AR Tonelli, ... European Respiratory Review 30 (162), 2021 | 9 | 2021 |
| Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat FF Rahaghi, VP Balasubramanian, RC Bourge, CD Burger, ... Pulmonary Circulation 12 (2), e12055, 2022 | 7 | 2022 |
| Long-Term effects of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease: the increase study open-label extension A Waxman, R Restrepo, T Thenappan, P Engel, A Bajwa, A Ravichandran, ... American Thoracic Society Conference, 2022 | 5 | 2022 |
| Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily S Shapiro, S Mandras, R Restrepo-Jaramillo, E Shen, M Broderick, Y Rao, ... Pulmonary Circulation 11 (4), 20458940211052228, 2021 | 5 | 2021 |
| Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the … K Zeitler, R Jariwala, R Restrepo-Jaramillo, S Kapadia, B Casanas, ... | 5 | 2018 |
| Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies NH Kim, KM Chin, VV McLaughlin, H DuBrock, R Restrepo-Jaramillo, ... Pulmonary Therapy 10 (1), 85-107, 2024 | 4 | 2024 |
| Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America M Orozco‐Levi, J Cáneva, C Fernandes, R Restrepo‐Jaramillo, N Zayas, ... Pulmonary Circulation 12 (1), e12012, 2022 | 4 | 2022 |
| Hepatopulmonary syndrome and portopulmonary hypertension R Restrepo, EF Singer, M Baram Hospital Practice 41 (2), 62-71, 2013 | 3 | 2013 |
| Blood Transfusion-Who Knows What to Do? A Survey of Medical House-Staff R Restrepo, M Baram, P Marik Chest 142 (4), 537A, 2012 | 3 | 2012 |
| Peripheral Blood Gene Expression Changes Predict Mortality and Treatment Response in Acute COVID-19 and Associate with Lung Fibrosis B Tourki, I Vera, C Perrot, F Farsaei, A Arsenault, B Juan-Guardela, ... C32. INTERROGATION OF GENETIC VARIATION, GENE EXPRESSION, AND OTHER …, 2022 | 2 | 2022 |
| BREEZE: Open-label, clinical study to evaluate the safety and tolerability of a treprostinil dry powder inhaler in patients with pulmonary arterial hypertension currently using … L Spikes, S Shapiro, R Restrepo-Jaramillo, J Joly, T Shah, J Scoggin, ... European Respiratory Journal 58 (suppl 65), 2021 | 2 | 2021 |
| The impact of inhaled treprostinil on patient lung function: results from the increase study A Waxman, R Restrepo, T Thenappan, A Ravichandran, P Smith, E Borg, ... Chest 158 (4), A2179-A2180, 2020 | 2 | 2020 |
| One Year Mortality Rates of Tracheostomy Cases: Life after the Knife R Restrepo, D Kahn, P Patel, B Awsare, M Baram J Emerg Med Trauma Surg Care 2 (006), 2015 | 2 | 2015 |
| A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil DL Zwicke, R Restrepo-Jaramillo, H Alnuaimat, K Gordon, M Broderick, ... Pulmonary Circulation 11 (1), 2045894021998203, 2021 | 1 | 2021 |
